One of the nation’s leaders in the fight against degenerative joint disease in equines, the veterinarian-trusted name of Adequan® (polysulfated glycosaminoglycan) has joined the United States Equestrian Federation family in a multi-faceted sponsorship. Luitpold Pharmaceuticals, manufacturer of the flagship equine health product, Adequan®, has stepped forward as title sponsor for three USEF championships for the 2005 competition season: the 2005 USEF National Open Reining Championship and the 2005 USEF National Pony Jumper Championships, both in Lexington, Kentucky, and the 2005 USEF National Junior Jumper Championships in Harrisburg, Pennsylvania. In addition, Adequan® has been designated “The Official Joint Therapy of the USEF.”
“For years, USEF members have relied on Adequan® i.m. as the joint disease treatment they trust for their horses,” says Allyn Mann, Senior Manager of the Animal Health Division at Luitpold. “They’ve shown a tremendous amount of confidence in our brand, our product and our results. They know from experience that we understand the needs of performance horses, and now, as we join the USEF family, the message will be clear—we support the vision of the sport as a whole and the devoted equestrians and horses who continue to move it forward.”
Due to the rigors of competition, many performance horses suffer from joint disease. Adequan® is designed to help treat the underlying cause of the problem and break the cycle of damage, while reducing pain and inflammation.
For full prescribing information on Adequan®, visit www.adequan.com.
There are no known contraindications to the use of intramuscular polysulfated glycosaminoglycan or PSGAG in horses. Studies have not been conducted to establish safety in breeding horses.